Branko Cuglievan, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Branko Cuglievan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07052994 · A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia PatientsM.D. Anderson Cancer Center · withdrawn · Pediatric Acute Leukemia · principal investigator
- Ph1NCT06474663 · A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasM.D. Anderson Cancer Center · withdrawn · Refractory Acute Leukemia, Relapsed Acute Leukemia · principal investigator
- Ph1NCT06448013 · A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- N/ANCT04889937 · Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric PopulationLeuko Labs, Inc. · completed · Hematologic Malignancy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.